かき肉エキスは非アルコール性脂肪性肝疾患モデルマウスにおける脂肪蓄積を低減する

抄録

We studied whether oyster extract protected a model mouse of non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) against steatosis and inflammation. Male C57BL/6JJmsSLC mice were randomly divided into 3 groups that were fed different diets for 6 weeks: the negative control group received a standard diet (AIN-93G), the positive control group were fed a choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD; to induce NASH) plus methionine and choline (at equivalent levels to those found in the oyster extract), and the oyster extract group were given the CDAHFD plus oyster extract. The serum biomarker levels of the mice were used as markers of liver failure. The histopathology of the liver and hepatic fibrosis (i.e., the mRNA levels of fibrosis-related genes such as Col1a1, Col3a1, Col4a1, and Ctgf) were examined in order to assess hepatic steatosis and inflammation, respectively. The mice fed the CDAHFD plus methionine and choline developed enlarged fatty livers and inflammation. However, treatment with oyster extract ameliorated the hepatic steatosis and inflammation induced by the CDAHFD. Moreover, a smaller CDAHFD-induced increase in fibrosis-related gene expression was seen in the livers of the mice fed oyster extract. These findings suggest that oyster extract suppresses non-alcoholic fatty liver disease by inhibiting steatosis.